MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation

NASDAQ:MLAB • US59064R1095

80.6 USD
+7.37 (+10.06%)
At close: Mar 11, 2026
80.6 USD
0 (0%)
After Hours: 3/11/2026, 8:13:09 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall MLAB gets a fundamental rating of 5 out of 10. We evaluated MLAB against 57 industry peers in the Life Sciences Tools & Services industry. MLAB scores excellent on profitability, but there are concerns on its financial health. MLAB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. MLAB Profitability Analysis

1.1 Basic Checks

  • MLAB had positive earnings in the past year.
  • In the past year MLAB had a positive cash flow from operations.
  • In multiple years MLAB reported negative net income over the last 5 years.
  • MLAB had a positive operating cash flow in each of the past 5 years.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • MLAB has a Return On Assets of 0.86%. This is in the better half of the industry: MLAB outperforms 64.91% of its industry peers.
  • Looking at the Return On Equity, with a value of 2.00%, MLAB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • MLAB has a Return On Invested Capital of 3.58%. This is in the better half of the industry: MLAB outperforms 64.91% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 11.85%.
  • The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.58%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • Looking at the Profit Margin, with a value of 1.51%, MLAB is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
  • MLAB's Operating Margin of 6.96% is fine compared to the rest of the industry. MLAB outperforms 64.91% of its industry peers.
  • In the last couple of years the Operating Margin of MLAB has grown nicely.
  • Looking at the Gross Margin, with a value of 62.40%, MLAB belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MLAB has grown nicely.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MLAB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
  • The number of shares outstanding for MLAB has been increased compared to 1 year ago.
  • The number of shares outstanding for MLAB has been increased compared to 5 years ago.
  • MLAB has a better debt/assets ratio than last year.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • MLAB has an Altman-Z score of 1.24. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
  • MLAB has a Altman-Z score (1.24) which is comparable to the rest of the industry.
  • MLAB has a debt to FCF ratio of 4.41. This is a neutral value as MLAB would need 4.41 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 4.41, MLAB is doing good in the industry, outperforming 71.93% of the companies in the same industry.
  • A Debt/Equity ratio of 0.86 indicates that MLAB is somewhat dependend on debt financing.
  • MLAB has a Debt to Equity ratio of 0.86. This is in the lower half of the industry: MLAB underperforms 78.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.24
ROIC/WACC0.34
WACC10.56%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.94, MLAB is doing worse than 63.16% of the companies in the same industry.
  • A Quick Ratio of 1.45 indicates that MLAB should not have too much problems paying its short term obligations.
  • MLAB's Quick ratio of 1.45 is on the low side compared to the rest of the industry. MLAB is outperformed by 68.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MLAB Growth Analysis

3.1 Past

  • MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.40%.
  • Measured over the past years, MLAB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -39.16% on average per year.
  • MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.12%.
  • MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 247.51% yearly.
  • Based on estimates for the next years, MLAB will show a small growth in Revenue. The Revenue will grow by 4.11% on average per year.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. MLAB Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 125.94, MLAB can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of MLAB is on the same level as its industry peers.
  • The average S&P500 Price/Earnings ratio is at 26.15. MLAB is valued rather expensively when compared to this.
  • Based on the Price/Forward Earnings ratio of 55.84, the valuation of MLAB can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. MLAB is valued rather expensively when compared to this.
Industry RankSector Rank
PE 125.94
Fwd PE 55.84
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 85.96% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 94.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.8
EV/EBITDA 12.81
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MLAB has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as MLAB's earnings are expected to grow with 247.51% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MLAB Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.73%, MLAB is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.10, MLAB pays a better dividend. On top of this MLAB pays more dividend than 96.49% of the companies listed in the same industry.
  • With a Dividend Yield of 0.73, MLAB pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.73%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has paid a dividend for at least 10 years, which is a reliable track record.
  • MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 93.97% of the earnings are spent on dividend by MLAB. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MLAB Fundamentals: All Metrics, Ratios and Statistics

MESA LABORATORIES INC

NASDAQ:MLAB (3/11/2026, 8:13:09 PM)

After market: 80.6 0 (0%)

80.6

+7.37 (+10.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.09%
Inst Owner Change-4%
Ins Owners5.44%
Ins Owner Change2.08%
Market Cap444.91M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (32.25%)
Short Float %4.06%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield 0.73%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)5.56%
PT rev (3m)10%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)19.12%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 125.94
Fwd PE 55.84
P/S 1.8
P/FCF 11.8
P/OCF 10.71
P/B 2.38
P/tB N/A
EV/EBITDA 12.81
EPS(TTM)0.64
EY0.79%
EPS(NY)1.44
Fwd EY1.79%
FCF(TTM)6.83
FCFY8.47%
OCF(TTM)7.52
OCFY9.34%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.04
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.24
F-Score6
WACC10.56%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.